|Training + Education
Hahnemann Medical College of Philadelphia; Boston University Medical Center; Emory University Medical Center; Grady Memorial Hospital
||Internal Medicine, Nephrology
Tufts Medical Center
800 Washington St., #391
Boston, MA 02111
2014, Physician of the Year from the Polycystic Kidney Disease Foundation
2014, Donald W. Seldin Distinguished Award from the National Kidney Foundation
2013, Top Doctor Boston Magazine
2012, "Top Doctor," Boston Magazine
2012, "Top Doctor" and in top 1% in the nation in his specialty, U.S. News & World Report
2009 Distinguished Faculty Award from TUSM
2007 Gift of Life Award - Outstanding Physician in Nephrology, National Kidney Foundation of MA, RI, NH and VT
2002, Citation for Excellence in Teaching by the Class of 2002 Tufts University School of Medicine
2001-2002 Tufts University School of Medicine Excellence in Teaching Award from the Third Year Medical Students
2000-2001, Tufts University School of Medicine Excellence in Teaching Award from the Third Year Medical Students
1. Perrone RD, Abebe KZ, Schrier RW, Chapman AB, Torres VE, Bost J, Kaya D, Miskulin DC, Steinman TI, Braun W, Winklhofer FT, Hogan MC, Tahbari-Oskoui F, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin D, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Bae KT; HALT PKD Study Group, Meyers CM. Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011;6:2508-15. Epub 2011 Sept 8.
2. Grantham JJ, Bennett WM, mTOR inhibitors and autosomal dominant polycystic kidney disease. N Engl J Med 2011;364:286-7; author reply 287-9.
3. Vora, N, Perrone, R, Bianchi, DW. Reproductive issues for adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Am J Kidney Dis 2008;51:307-18.
4. Alam A, Perrone, RD. Managing cyst infections in ADPKD: an old problem looking for answers. Clin J Am Soc Nephrol; 4:1154-1155, 2009.
5. Chapman, AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, Miskulin DC, Oskoui FR, Masoumi A, Hogan MC, Winklhofer FT, Braun W, Thompson PA, Meyers CM, Schrier RW. The Halt Polycystic Kidney Disease Trials: design and implementation. Clin J Am Soc Nephrol;5102-9,2010.
6. Alam A, Perrone RD. Management of the ESRD in patients with autosomal dominant polycystic kidney disease. Adv Chron Kid Dis;17:164-172,2010.
7. Grantham JJ, Bennett WM, Perrone RD. mTOR inhibitors and automal dominant polycystic kidney disease. N Engl J Med; 364:286-287; author reply 287-289,2011.
8. Heffernan KS, Kuvin JT, Sarnak MJ, Perrone RD, Miskulin DC, Rudym D, Chandra P, Karas RH, Menon V. Peripheral augmentation index and vascular inflammation in autosomal dominent polycystic kidney disease. Nephrol Dial Transpl; epublication February 3, 2011.
Member, Scientific Advisory Committee (former Chairperson), Polycystic Kidney Disease Foundation
Member, Board of Trustees, Polycystic Kidney Disease Foundation
Region 1 Representative, OPTN/UNOS Kidney Transplant Committee
Chair, UNOS Region 1 Renal Transplant Oversight Committee.
Editorial Board, Clinical Journal of the American Society of Nephrology
Dr. Perrone’s patient care interests are in polycystic kidney disease, general nephrology, acid-base disorders, hypertension, and kidney transplantation medicine. He is the Director of the Polycystic Kidney Disease Center.
Dr. Perrone’s research interests are largely focused in the area of polycystic kidney disease, including slowing progression and determining the natural history of the extrarenal complications. In prior studies, he addressed the mortality of extrarenal complications of polycystic kidney disease after kidney failure treated by dialysis. He will continue this work in collaboration with Drs. Alan Collins and Blanche Chavers of the United States Renal Data System.
Dr. Perrone also is the Principal Investigator of the Boston Patient Care Center of an NIH-funded multi-center clinical trial (HALT Progression in PKD, part of the Polycystic Kidney Disease Clinical Trials Network). This study uses angiotensin converting enzyme inhibitors in combination with angiotensin receptor blockers to slow the progression of polycystic kidney disease and utilizes the unique endpoint of kidney volume growth as assessed using magnetic resonance imaging. Tufts Medical Center is one of the four national HALT-PKD Study centers that will conduct this 6-year, $25 million study sponsored by the NIH. Drs. Perrone (the PI) and Miskulin direct the study that started in the winter of 2006.
Dr. Perrone is the Tufts Medical Center Principal Investigator of the TEMPO 3/4 study. TEMPO 3/4 is a global trial that is addressing the efficacy of the vasopressin-receptor antagonist tolvaptan to slow progression of polycystic kidney disease. The unique endpoint of kidney volume growth will be assessed using magnetic resonance imaging. Tufts Medical Center is one of 100 international TEMPO 3/4 Study centers.